• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ANAB

ANAB

AnaptysBio, Inc.

NASDAQHealthcareBiotechnologyUS

USD51.24

-0.02 (-0.04%)

Rating:D+

Company Profile

CEO

Daniel R. Faga

IPO Date

2017-01-26

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$52.05

Prev. Close

$51.26

Day Low

$50.19

Day High

$52.51

52W Low

$11.40

52W High

$72.36

Market Cap

$2.21B

Volume

0.78M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

40.0%

Avg Negative

2.0%

Avg Neutral

57.9%

News Feed

AnaptysBio Shares Increase Over 5% Pre-Market: Why It Happened

Pulse2·8/18/2021·↑ positive

AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication

Benzinga·8/18/2021·↑ positive

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

GlobeNewsWire·8/17/2021
·↑ positive

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·8/9/2021·↑ positive

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

GlobeNewsWire·8/9/2021·↑ positive

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/27/2021·↑ positive

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/4/2021·↓ negative

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

GlobeNewsWire·4/23/2021·↑ positive

Why AnaptysBio Stock Is Attractive After 30% Selloff

Benzinga·3/16/2021·↑ positive

Why AnaptysBio Stock Is Popping Today

The Motley Fool·3/16/2021·↑ positive